Coherus Oncology (CHRS) Competitors $0.81 +0.07 (+8.84%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$0.80 -0.01 (-1.38%) As of 07/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. AMRN, PRTA, TERN, PRME, HUMA, AQST, SNDL, HRTX, AURA, and ALTShould you be buying Coherus Oncology stock or one of its competitors? The main competitors of Coherus Oncology include Amarin (AMRN), Prothena (PRTA), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Humacyte (HUMA), Aquestive Therapeutics (AQST), SNDL (SNDL), Heron Therapeutics (HRTX), Aura Biosciences (AURA), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry. Coherus Oncology vs. Its Competitors Amarin Prothena Terns Pharmaceuticals Prime Medicine Humacyte Aquestive Therapeutics SNDL Heron Therapeutics Aura Biosciences Altimmune Amarin (NASDAQ:AMRN) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends. Do institutionals & insiders hold more shares of AMRN or CHRS? 22.3% of Amarin shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 2.0% of Amarin shares are held by insiders. Comparatively, 8.1% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer AMRN or CHRS? Amarin currently has a consensus price target of $12.00, suggesting a potential downside of 28.70%. Coherus Oncology has a consensus price target of $4.68, suggesting a potential upside of 476.62%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media prefer AMRN or CHRS? In the previous week, Amarin and Amarin both had 1 articles in the media. Coherus Oncology's average media sentiment score of 0.00 beat Amarin's score of -0.13 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is AMRN or CHRS more profitable? Amarin has a net margin of -41.07% compared to Coherus Oncology's net margin of -66.30%. Coherus Oncology's return on equity of 0.00% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-41.07% -17.21% -12.16% Coherus Oncology -66.30%N/A -26.51% Which has more risk and volatility, AMRN or CHRS? Amarin has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Which has better valuation and earnings, AMRN or CHRS? Coherus Oncology has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M1.52-$82.18M-$3.64-4.62Coherus Oncology$266.96M0.35$28.51M-$1.13-0.72 SummaryCoherus Oncology beats Amarin on 12 of the 15 factors compared between the two stocks. Get Coherus Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.51M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-0.7220.8027.0020.10Price / Sales0.35286.98435.75120.29Price / Cash2.5641.1936.8257.86Price / Book-0.717.487.985.56Net Income$28.51M-$55.04M$3.16B$248.40M7 Day Performance2.15%2.44%2.40%4.67%1 Month Performance-4.94%1.90%2.19%6.64%1 Year Performance-43.99%4.35%33.82%21.31% Coherus Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus Oncology3.7126 of 5 stars$0.81+8.8%$4.68+476.6%-36.0%$86.51M$266.96M-0.72330Gap UpAMRNAmarin0.6005 of 5 stars$16.22+3.2%$12.00-26.0%+13.8%$335.92M$228.61M-4.46360Gap UpHigh Trading VolumePRTAProthena3.0398 of 5 stars$6.07-0.2%$31.50+418.9%-67.7%$326.75M$135.16M-2.92130TERNTerns Pharmaceuticals3.6991 of 5 stars$3.73-2.6%$15.63+318.9%-39.8%$325.78MN/A-3.4240PRMEPrime Medicine4.0479 of 5 stars$2.47+2.1%$10.08+308.2%-25.3%$324.30M$3.85M-1.20234News CoverageOptions VolumeHigh Trading VolumeHUMAHumacyte2.7386 of 5 stars$2.09-1.4%$11.71+460.5%-54.7%$324.20M$1.57M-3.03150News CoverageGap UpAQSTAquestive Therapeutics1.2383 of 5 stars$3.31+1.8%$10.14+206.4%+53.3%$322.82M$54.23M-5.61160SNDLSNDL3.5078 of 5 stars$1.21-1.6%$3.63+199.6%-29.9%$317.96M$671.81M-4.172,516News CoveragePositive NewsHRTXHeron Therapeutics3.9253 of 5 stars$2.07-3.3%$5.00+141.5%-25.9%$315.80M$144.29M-34.50300AURAAura Biosciences1.8805 of 5 stars$6.26-0.3%$22.00+251.4%-14.6%$314.69MN/A-3.2950ALTAltimmune2.1994 of 5 stars$3.87+10.6%$19.00+391.0%-33.5%$313.90M$20K-3.0750Gap DownHigh Trading Volume Related Companies and Tools Related Companies Amarin Alternatives Prothena Alternatives Terns Pharmaceuticals Alternatives Prime Medicine Alternatives Humacyte Alternatives Aquestive Therapeutics Alternatives SNDL Alternatives Heron Therapeutics Alternatives Aura Biosciences Alternatives Altimmune Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
